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Abstract
Background/Aims: Determination of peptide biomarkers such as troponins, natriuretic 
peptides or the recently reported FGF23 can be useful to identify hemodialysis patients with a 
high risk of mortality. However, it is desirable to focus on few robust parameters to warrant their 
routine application. Methods: In a prospective cohort study with 239 prevalent hemodialysis 
patients we studied the prognostic significance of 10 simultaneously determined modern 
peptide biomarkers (high sensitive troponin I and T, NT-pro-BNP, BNP, MR-pro-ANP, MR-
pro-ADM, CT-pro-ET1, copeptin, FGF23 and a-Klotho) and compared them with parameters 
traditionally associated with mortality (PTH, Ca, Pi, albumin, CRP, cholesterol, AP). Results: 
After a follow-up of 4 years, plasma concentration of troponins, natriuretic peptides, MR-pro-
ADM, FGF23 as well as PTH, CRP, AP were significantly higher in deceased patients (n=95). 
Hazard ratios from cox regression on a continuous scale (doubling of plasma concentration) 
or relative in tertiles were highest for high sensitive troponins, followed by natriuretic peptides 
and MR-pro-ADM (1.6-2.0 and 2.3-5.5, resp.). C-indices were also highest for troponins 
(0.708-0.746), followed by natriuretic peptides (0.706-0.731). Traditional parameters had low 
c-indices (0.598-0.655). Stepwise cox regression revealed that among all parameters troponin 
I, NT-pro-BNP, PTH and CRP remained independent predictors of mortality and a composite 
score had the highest c-index (0.799 [0.740-0.849]). Conclusions: Among peptide biomarkers 
high sensitive troponins and to a lesser extent natriuretic peptides are strong predictors 
of mortality in asymptomatic hemodialysis patients, followed by markers of mineral-bone 
disease and inflammation. 
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Introduction
Accurate risk prediction and identification of asymptomatic hemodialysis patients 
with a high risk of mortality is an important clinical task. In addition to many clinical or 
functional variables associated with mortality such as age [1], dialysis vintage [2], cardiac 
function [3] and physical status /frailty [4], laboratory parameters have also been shown to 
predict mortality. 1990 Lowrie et al. first published that albumin, creatinine, cholesterol and 
calcium among others were predictors of mortality in hemodialysis patients [5]. Since then, 
numerous other laboratory parameters have been found to be associated with mortality 
including c-reactive protein (CRP) [6, 7], interleukin-6 [8], parathyroid hormone (PTH) [9], 
homocysteine [10], troponins [11], natriuretic peptides [12, 13] and most recently fibroblast 
growth factor 23 (FGF23) [14]. Many of these parameters are peptides that are secreted 
in increased amounts during the course of end-stage renal disease: they can be termed as 
biomarkers because their plasma concentration is linked to severity of disease state and 
outcome [15]. In particular, cardiac biomarkers such as troponins and natriuretic peptides 
are among the strongest biomarkers in maintenance hemodialysis patients. In their meta-
analyses, Khan et al. and Cheng et al. found that an elevated plasma troponin and natriuretic 
peptide concentrations were associated with a 2.64- and 3.85-fold increase, respectively, in 
the relative risk for all-cause mortality, [16, 17]. 
Despite their prognostic significance, many peptide biomarkers are not utilized in 
daily practice in contrast to common parameters such as parathyroid hormone, albumin 
or creatinine for several reasons. First, many peptide biomarkers are not required to guide 
renal replacement therapy and the treatment of other commons complications of ESRD 
patients including renal anemia or mineral-bone disease. Second, the interpretation of their 
plasma concentrations is complex because hemodialysis patients often exhibit high plasma 
concentrations making it difficult to distinguish between mere accumulation and increased 
release. Third, it is unclear which biomarker the clinician should rely on as there are many 
candidates which differ in their strength of association with mortality and studies describing 
the prognostic significance of biomarkers with a c-statistic or hazard ratios cannot be 
compared directly. Thus, from a clinician´s point of view it would be highly desirable to focus 
on single parameters with a high predictive value that are validated in hemodialysis patients 
with specific cut-off values. 
In previous studies, our group has investigated the performance of various modern 
peptide biomarkers in stable hemodialysis patients that were newly developed and had 
been scarcely tested in this cohort. These studies included high sensitive troponins T and 
I, natriuretic peptides (MR-pro-ANP, BNP, NT-pro-BNP), vasoactive peptides (copeptin, MR-
pro-adrenomedullin, CT-pro-endothelin), FGF23 and alpha-Klotho [18-21]. With the current 
study, we wanted to find out, which of these biomarkers could qualify for risk prediction 
on a routine basis in asymptomatic hemodialysis patients. To this end we compared the 
performance of ten of these modern peptide biomarkers that were measured in the same 
hemodialysis cohort at the same time point with regard to the prediction of mortality during 
a 4.4-year follow-up and compared them to traditional laboratory markers associated with 
mortality.
Subjects and Methods
Patients and cohort
This prospective multicenter study included stable ambulatory hemodialysis patients from four 
dialysis centers in Southwest Germany between September 2009 and April 2010. Patients were included 
after they provided written informed consent and if there was no evidence of an acute illness, a cardiac 
event or a procedure within the previous two months. Patients with cardiac diseases leading to increased 
cardiac biomarkers concentration (troponin, natriuretic peptides) independent of ESRD, such as amyloidosis 
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were excluded. The study was approved by the local ethics committee of the University of Tuebingen 
(191/2009BO2).
Laboratory assays
Plasma concentrations of the parameters were measured in three independent samples that were 
taken within two weeks prior to the start of a dialysis session. Blood was collected in lithium-heparinized 
tubes (Sarstedt, Nuembrecht, Germany), cooled at 4°C and centrifuged within four hours; plasma samples 
were stored at -80°C for further analysis. The plasma concentrations of troponin I and T were measured 
using the troponin I Ultra assay on a Siemens ADVIA Centaur system (Siemens Healthcare Diagnostics, 
Eschborn, Germany) and using the high sensitive troponin T assay on an Elecsys 2010 system (Roche, Basel, 
Switzerland), respectively. BNP and NT-pro-BNP were measured on a Siemens ADVIA Centaur and Siemens 
Immulite 2000 XPi system, respectively, as specified by the manufacturers. MR-pro-ANP, copeptin, MR-
pro-ADM and CT-pro-ET1 were measured using an automated immunoluminometric assay on a Kryptor 
system (B.R.A.H.M.S AG, Henningsdorf, Germany) as previously described in [22-24]. Plasma FGF23 and 
alpha-Klotho concentration were manually measured using ELISA methods (Immuno-Biologic Laboratories 
Co., Ltd. Japan; and Immutopics, San Clemente, CA, USA, respectively) [21]. Plasma beta-2-microglobulin 
concentrations were measured using a turbidimetric assay (Randox Laboratories, Antrim, United Kingdom). 
All other laboratory values (i.e., parathyroid hormone, hemoglobin, albumin, C-reactive protein, calcium, 
alkaline phosphatase, total cholesterol and inorganic phosphorus) were extracted from the patients’ medical 
records and averaged from the available values of the previous year (4 – 12 values).
Statistical analysis
Three plasma samples were available from 87% of the patients and were averaged to calculate the 
arithmetic mean without excluding possible outliers. Plasma concentrations were log10 transformed to 
approximate normal distribution. The follow-up period started on the first day of blood draw and lasted 
until August 25th, 2014. Patients receiving renal transplantation were censored at the day of transplantation. 
Causes of death were classified according to the best knowledge of each particular case. To analyze 
cardiovascular mortality separately, the follow-up of the patients who died from non-cardiovascular death 
was censored at the day of their death taking into account that patients dying from non-cardiovascular 
causes are no longer at risk of dying from cardiovascular  causes. The averaged values of the deceased 
patients were compared to those from the surviving patients using a two-sided t-Test. Mortality was 
analyzed in quintiles to rule out a j-curved relationship which would hinder Cox proportional regression 
analysis. Univariate and multivariate proportional hazards were then calculated using the Cox proportional 
regression analysis. Prognostic performance was analyzed using the c-index. Cut-off values were calculated 
by maximizing sensitivity and 1-specificity (Youden index). C-indices were compared using the method of 
Hanley & McNeil [25]. Calibration of the models was tested using the Hosmer-Lemeshow-Test. 
Data analysis was performed using the statistical software package MedCalc Statistical Software 
version 13.3 (MedCalc Software bvba, Ostend, Belgium) and JMP 10.0.1 (SAS Institute, Cary, NC, USA). A 
p-value <0.05 was considered statistically significant.
Results
Patients 
From a total of n = 250 patients treated in the participating centers, 239 patients 
(95.6%) were included in the study. 6 patients declined written informed consent, 2 died 
within the period of blood sampling, 2 had cardiac amyloidosis and one patient was only 
recently started on dialysis. The baseline characteristics of the study cohort are given in table 
1. 
Association with mortality
After 4.4 years, follow-up data on all 239 patients were available (median follow-up 
time 1676 days [IQR 1623; 1727]). Of these patients, 95 died (40%) and 17 (7%) received 
kidney transplantation (table 2). A comparison of the median plasma concentrations of the 
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To compare the strength of the 
relationship of the individual pa-
rameter with all-cause mortality, 
hazard ratios (HR) from cox regres-
sion analysis were calculated on 
both a continuous scale and a rela-
tive scale based on tertiles. Although 
HR values on a continuous scale are 
difficult to directly compare due to 
differences in the variability and am-
plitude of each parameter, HR values 
in relation to the lowest tertile of 
each marker might circumvent this. 
As shown in Fig 1, unadjusted HR for 
the doubling of the plasma concen-
tration were highest for troponin T, 
followed by MR-pro-ADM, MR-pro-
ANP and troponin I. When adjusting 
Table 1. Baseline characteristics of the cohort (N=239). Values are shown as median 
and interquartile range for continuous variables and as percentages for categorical 
variables.  
Table 2. Follow-up data after 4.6 (IQR 4.4;4.7) years and 
causes of death
studied labora-
tory parameters 
between sur-
vivors and de-ceased patients 
is shown in table 
3. Among mod-
ern biomarkers, 
all parameters 
related to cardi-
ac health were 
highly differ-
ent as well as 
M R - p r o - A D M 
and FGF23, a 
parameter re-
lated to mineral 
bone. Among 
the traditional 
parameters CRP, 
PTH, AP, but not 
albumin, were 
higher in the de-ceased patients 
than in survi-
vors. All of pa-
rameters had a 
linearly increas-
ing relationship 
with mortality. 
Prognostic 
value of sin-
gle param-
eters
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for different demographic (model 1) or survival-associated variables (model 2), HR values 
were attenuated, but still were significantly different from unity in almost all studied param-
eters. When analyzing unadjusted and adjusted HR values normalized to the lowest tertile 
of each parameter, troponin T and I again had the highest values, followed by the natriuretic 
Table 3. Plasma concentrations of laboratory parameters in the whole cohort and in survivors versus de-
ceased patients. Values are shown as median with interquartile range.
Fig. 1. Hazard ratios (and 95% CIs) for all-cause mortality on a continuous scale (A) for a two-fold increase 
and on a relative scale with the lowest tertile serving as reference (B). Model 1 is adjusted for demographics, 
blood pressure and dialysis-specific risk factors (time on dialysis, residual diuresis, vascular access and sin-
gle pool Kt/V). Model 2 is adjusted for all factors associated with mortality (significant difference between 
deceased and surviving patients): age, body mass index, duration of HD session, diastolic blood pressure, 
comorbidities: systolic dysfunction (1=yes), peripheral vascular disease (1=yes), coronary artery disease 
(1=yes), atrial fibrillation (1=yes).
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peptides indicating a strong relationship of all-cause mortality with these parameters. C-in-
dices of the parameters associated with mortality were calculated to analyze the prognostic 
performance regarding the discrimination of deceased patients. Troponins showed the high-
est values for the c-index, followed by natriuretic peptides. Among traditional biomarkers, 
CRP had the highest c-index. When analyzing cardiovascular mortality, c-indices were slight-
ly higher, particularly for the cardiac biomarkers. Interestingly, c-index of CRP was lower 
indicating an attenuated relationship to cardiovascular mortality (table 4).
Calibration of the parameters with regard to the prediction of risk compared the 
observed risks was tested using the Hosmer-Lemeshow test. Both modern biomarkers as 
well as traditional parameters showed a good calibration (p values from 0.10-0.98 and 0.57-
0.88, respectively).
Prognostic value of multiple parameters
To find out parameters independently associated with mortality that could be 
summarized into a composite risk score, a proportional cox regression with a stepwise 
approach and retention if p<0.05 was performed. Among all of the parameters listed in table 
3, four parameters were highly independent predictors of mortality and could be combined 
in a multivariate model: troponin I (p<0.0001), NT-pro-BNP (p=0.0290), CRP (p=0.0072) 
and parathyroid hormone (p=0.0064). Using a calculated score derived from troponin I (beta 
1.1293), NT-pro-BNP (beta 0.5098), CRP (beta 0.8251) and parathyroid hormone (beta 
0.9812), the c-index could be improved up to 0.799 [0.740-0.849], a value statistically higher 
than the respective value derived from single parameters (p between <0.0001 and 0.0131; 
Fig 2). The cut-off value was 6.0498 and had a sensitivity and specificity of 85% and 63%, 
respectively. The calculated score correctly reclassified 3%, 3%, 10% and 6%, of the patients 
compared to using trop I, NT-pro-BNP, CRP and PTH alone. 
When analyzing cardiovascular mortality as endpoint in a stepweise multivariate Cox 
regression model, only troponin I (p=0.0008), BNP (p=0.0095) and parathyroid hormone 
(p=0.0370) were independent predictors. Using a calculated score derived from these, the 
c-index could be improved up to 0.804 [0.748-0.852]. The cut-off value was 8.5523 and had 
a sensitivity and specificity of 68% and 85%, respectively.
Fig. 2. ROC curves showing the 
prognostic performance of predict-
ing all-cause mortality for troponin 
I, NT-pro-BNP, CRP and PTH as well 
as a composite score of these four 
parameters. Note that the c-index of 
the composite model (0.799) is sig-
nificantly higher than that derived 
from each parameter (TnI 0.746; 
NT-pro-BNP 0.731, CRP 0.655, PTH 
0.614).
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Discussion 
This study allows for the direct quantitative comparison of different peptide 
biomarkers in predicting mortality in chronic hemodialysis patients. The main finding 
was that high sensitive cardiac troponins and natriuretic peptides were the strongest 
predictors of mortality among the tested biomarkers.  In the absence of acute myocardial 
injury or ischemia, cardiac troponins and natriuretic peptides are robust markers of cardiac 
dysfunction and reflect myocardial integrity in chronic hemodialysis patients. In a previous 
study with this cohort, systolic left ventricular function estimated from echocardiography 
was the main determinant of the plasma concentration of cardiac biomarkers and also the 
strongest independent predictor of mortality [18, 20]. Among cardiac biomarkers, troponin 
T and NT-pro-BNP revealed largely elevated plasma concentration due to accumulation as 
excretion was related to residual renal function in contrast to troponin I [18, 19]. Along the 
same lines, the cut-off of troponin T and NT-pro-BNP derived from c-indices was higher 
than used for non-HD patients (Table 4). For troponin I, the cut-off was 14 pg/ml, which 
was still lower than the 99th percentile that is used as a threshold for the diagnosis of acute 
myocardial infarction. 
Among the other modern peptide biomarkers, only MR-pro-ADM and FGF23 showed 
an association with mortality and among the traditional biomarkers, parathyroid hormone, 
AP and CRP were associated with mortality. However, their association was rather weak and 
showed great overlap between survivors and deceased patients (table 3) which precludes 
their use for risk stratification and prognostication. According to Swets [26], a good diagnostic 
test is characterized by a c-statistic value above 0.8 and only the composite measure 
consisting of troponin I, NT-pro-BNP, parathyroid hormone and CRP approached this value. 
Due to their low sensitivity and specificity, biomarkers tested in this study performed better 
in identifying low risk patients compared to high risk patients (higher negative predictive 
values).
Table 4. C-statistics of the parameters associated with all-cause and cardiovascular (CV) mortality.
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The findings in this study underscore the utmost importance of cardiac health in the 
prognosis of hemodialysis patients as cardiac biomarkers reflect a failing heart and features 
of the renocardiac syndrome. Troponins measured with a high sensitive assay may provide 
high resolution to identify patients at high risk. Interestingly, prognostication could be 
significantly improved by adding parathyroid hormone and CRP to the model. This points to 
mineral bone disorder and chronic inflammation as additional areas highly relevant for the 
mortality risk of asymptomatic hemodialysis patients. In this study, parathyroid hormone 
was the only independent predictor among the markers of bone mineral disorder and 
outperformed FGF23. This interesting finding indicates that secondary hyperparathyroidism 
is a potent surrogate of CKD-MBD-associated mortality in hemodialysis patients justifying 
the current practice of routinely measuring PTH. An explanation for this might be the 
delayed kinetic of parathyroid hormone secretion that relies on more profound changes in 
the calcium and phosphorus metabolism compared to FGF23 that is more volatile. In our 
data, this was reflected by a higher coefficient of variation (CV) of FGF compared to PTH 
(30% vs. 16%). 
Another important predictor of mortality, albumin, did not play a role in this cohort 
although there were patients with low albumin concentration (25% below 35 g/l) that 
should be at high risk of mortality. In the study of Kalantar-Zadeh [27], baseline albumin 
concentration was an independent predictor of mortality in hemodialysis patients. However, 
in the same study, time-varying albumin concentration based on quarterly measurements 
of serum albumin (up to 8 albumin values per patient over 2 years) substantially lost its 
strength of association to mortality [27]. In our study, albumin concentrations were derived 
from the average of the values available from the patient´s medical records (4-6 values) 
which resembled time-varying values. 
The limitations of this study may be its relatively small sample size compared to data 
from randomized controlled trials (RCT) such as the 4D study [28] or large registries such as 
the DOPPS that were able to disclose even weak prognostic associations [29, 30]. In the above 
mentioned study by Kalantar-Zadeh et al. [27], the association of albumin concentration and 
mortality was analyzed in a sample of 58 058 patients yielding a high statistical power to find 
significant associations even with small HR values. However, no c-indices are usually provided 
in these large studies that could tell the clinician how predictive the concentration of the 
tested laboratory marker is for the individual patient. In a new analysis of the DOPPS study, a 
model with serum albumin and age reached a c-statistic of 0.72 [31]. Thus, associations seen 
in large studies are often not visible in the routine practice of nephrologists. Additionally, 
strict inclusion criteria often impair the generalizability of results from RCTs. In this cohort, 
there were minimal inclusion criteria, and the results thus more likely reflect the daily 
practice pattern of a nephrologist. Due to the small size of our cohort we could not divide 
the sample into a training and validation set, hence our findings must be validated in other 
independent hemodialysis cohorts. Another limitation is that not all analyzed parameters 
were measured from the same sample, and values for PTH, CRP and albumin were extracted 
from the records.  
Our study shows that the prognostic information that can be obtained from peptide 
biomarkers is very high for cardiac markers making them a candidate for routine clinical risk 
stratification although there is no evidence-based strategy how to improve outcome while 
lowering plasma concentrations. Additionally, there are virtually no data on the prognostic 
association of the change of cardiac biomarkers with time, and this study also was based 
on the measurement of the biomarkers at one time point. Thus, studies on the longitudinal 
course of biomarkers would be helpful to decide about the clinical usefulness of measuring 
biomarkers on a routine basis.
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